immune system news from FierceBiotech
News
IRX Therapeutics raises $25M Series A
New York-based IRX Therapeutics announced that it has raised $25 million in a Series A. The new money will be used to further develop IRX's cancer and viral disease product platform, including IRX-2 Read more...
Antigenics gets world's first cancer vaccine approval
Russia has improbably emerged as a world leader in new cancer vaccines. The country's regulatory body approved the use of Read more...
Pharming shares sink after Rhucin gets thumbs down
There's new trouble for Pharming's Rhucin, an experimental treatment for hereditary angioedema. Pharming shares plunged after the company announced that the EMEA's Committee for Medicinal Products Read more...
Breakthrough reported in flu vaccine research
A Japanese chemical company saw its stock shoot up 20 percent this morning, the maximum allowed on the Japanese market, after researchers for NOF and Japan's National Institute of Infectious Diseases Read more...
Wyeth takes another look at antibody pact
In yet another sign of monoclonal antibodies' popularity among big drug developers, Wyeth has extend its evaluation of selected Raven Biotechnologies MAb antibodies. Raven, which signed a pact with Read more...
Pfizer buys Coley for $164M
In what is sure to be one of many acquisitions to come, Pfizer has agreed to purchase Wellesley, MA-based Coley Pharmaceuticals for $8 per share, bringing the total deal to $164 million. Pfizer will Read more...
SPOTLIGHT: Argos, J&J make a deal
Therakos, a Johnson & Johnson company, has struck a licensing deal with Argos Therapeutics. Therakos gains Arros' technology related to part of the immune system known as regulatory T cells. Read more...
Momenta shares tumble after FDA rejection
It's Momenta Pharmaceuticals' turn at the Wall Street whipping post as investors respond to the news that the FDA has rejected its Read more...
Big Pharma takes an interest in cancer vaccines
For two decades, biotech companies have struggled to develop therapeutic cancer vaccines designed to treat the disease by stimulating the immune system to attack cancer cells without harming normal Read more...
SPOTLIGHT: Big Pharma takes an interest in cancer vaccines
For two decades, companies have struggled to develop therapeutic vaccines designed to treat cancer by stimulating the immune system to attack cancer cells without harming normal cells. So far, the Read more...
Get more immune system coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets